Moxifloxacin EP Impurity E (2HCl)
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Moxifloxacin EP Impurity E (2HCl)

● Auf Lager

Katalog-Nr.::VE009652
CAS-Nr.::N/A
Summenformel::C20H22FN3O4 .2HCl
Molare Masse::460.33 g/mol

Zusätzliche Informationen zu Moxifloxacin EP Impurity E (2HCl)

Parent drug

Moxifloxacin

IUPAC-Name

1-Cyclopropyl-6-fluoro-8-hydroxy-7-[(4aS, 7aS)-octahydro-6H-pyrrolo [3, 4-b]pyridin-6-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid dihydrochloride

Synonyme

Moxifloxacin Related Compound E / Moxifloxacin O-Desmethyl Analog

Beschreibung

Also known as Moxifloxacin Related Compound E or Moxifloxacin O-Desmethyl Analog, it is one of impurity present in Moxifloxacin, the bactericidal action of moxifloxacin results from the inhibition of the enzymes topoisomerase II and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication and repair of bacterial DNA. Topoisomerase IV is an enzyme that acts on the partitioning of the chromosomal DNA during bacterial cell division. which is used in the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis.

References

Tulkens, P. M., Arvis, P., & Kruesmann, F. (2012). Moxifloxacin Safety. Drugs in R&D, 12(2), 71–100. https://doi.org/10.2165/11634300-000000000-00000

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url